Search
Boston Scientific Corp
BSXAdd to Watchlist
44.205USD
-0.255-0.57%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
65.70BMarket Cap
18.39P/E TTM
More Details of Boston Scientific Corp Company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Boston Scientific Corp Info
Ticker SymbolBSX
Company nameBoston Scientific Corp
IPO dateMay 19, 1992
CEOMahoney (Michael F)
Number of employees53000
Security typeOrdinary Share
Fiscal year-endMay 19
Address300 Boston Scientific Way
CityMARLBOROUGH
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code01752-1234
Phone15086834000
Websitehttps://www.bostonscientific.com/en-US/Home.html
Ticker SymbolBSX
IPO dateMay 19, 1992
CEOMahoney (Michael F)
Company Executives of Boston Scientific Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.86M
+0.66%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
45.38K
+8.37%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.99K
--
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
27.93K
+13.60%
Mr. David C. Habiger
Mr. David C. Habiger
Independent Director
Independent Director
13.88K
+59.45%
Mr. Yoshiaki Fujimori
Mr. Yoshiaki Fujimori
Independent Director
Independent Director
2.08K
--
Mr. Joseph M. Fitzgerald
Mr. Joseph M. Fitzgerald
Executive Vice President, Group President - Cardiology
Executive Vice President, Group President - Cardiology
--
--
Mr. Edward J. Ludwig
Mr. Edward J. Ludwig
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael F. (Mike) Mahoney
Mr. Michael F. (Mike) Mahoney
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.86M
+0.66%
Mr. John E. Sununu
Mr. John E. Sununu
Independent Director
Independent Director
54.72K
--
Mr. Vance R. Brown
Mr. Vance R. Brown
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
54.24K
--
Mr. David S. (Dave) Wichmann
Mr. David S. (Dave) Wichmann
Independent Director
Independent Director
45.38K
+8.37%
Mr. Jonathan R. Monson
Mr. Jonathan R. Monson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
37.99K
--
Ms. Ellen M. Zane
Ms. Ellen M. Zane
Independent Director
Independent Director
27.93K
+13.60%
FAQs
Who are the top five shareholders of Boston Scientific Corp?
The top five shareholders of Boston Scientific Corp are: Mr. Michael F. (Mike) Mahoney
How many institutions hold shares of Boston Scientific Corp (BSX)?
As of 2026Q1, 3113 institutions hold shares of Boston Scientific Corp, with a combined market value of approximately 1.40B, accounting for 94.35% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -15512534.00.
What is the biggest source of revenue for Boston Scientific Corp?
In 2026Q1, the Interventional Cardiology Therapies business generated the highest revenue for Boston Scientific Corp, amounting to 4.64B and accounting for 23.11% of total revenue.
